Drug Interactions That Show Up on Boards and at the Bedside

Drug interactions are where pharmacology stops being academic. They’re favorites of board writers because they test integrated reasoning, and they’re a daily safety concern because a dangerous combination rarely announces itself. A handful come up over and over, on exams and in practice alike:

• Serotonergic combinations — SSRIs/SNRIs stacked with tramadol, triptans, linezolid, or each other, and the serotonin syndrome that can follow.
• Warfarin’s long list — antibiotics, antifungals, amiodarone, and NSAIDs that swing the INR or add bleeding risk.
• QT prolongers — the additive risk when two or more (certain antiarrhythmics, macrolides, antipsychotics, ondansetron) are combined.
• CYP interactions — inhibitors and inducers that raise or crater the levels of statins, immunosuppressants, and more.
• Potassium traps — ACE inhibitors, ARBs, spironolactone, and potassium supplements converging toward hyperkalemia.
• NSAID pitfalls — blunting antihypertensives and compounding renal and bleeding risk.

What makes these worth deliberate review is that they’re pattern-based: once you recognize the mechanism, you catch the whole family, not just the one example a question happens to use. The Pharmacology Review Course teaches them that way — 12.5 hours of AAPA Category 1 CME, organized so the interactions connect to the classes you’re already reviewing, with explanations that build the pattern rather than asking you to memorize a list. It’s $499.99 for 30 months, with the optional $100–$1,500 Amazon or Apple gift-card add-on.

Master high-yield interactions with CME →